Research · 10 min read
GLP-1s and Oral Birth Control: Which Labels Carry a Warning, and Which Do Not
Three of these labels tell people on the pill to switch methods or add a barrier one, on a clock tied to the first dose and to every step up. Two others report that the interaction was studied and was not clinically meaningful. The difference is the molecule, not the category.
Key takeaways
- This is not a class effect. Three of these labels warn about oral hormonal contraceptives and two report that the interaction was studied and was not clinically meaningful.
- The tirzepatide labels advise switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose escalation.
- The orforglipron label gives the same advice on a 30-day clock, while stating the effect has not been evaluated in a clinical trial.
- All three warning labels state that hormonal contraceptives not taken by mouth are not expected to be affected.
- The semaglutide labels name ethinyl estradiol and levonorgestrel among drugs showing no clinically significant pharmacokinetic difference.
- The same gastric-emptying mechanism reaches other swallowed drugs, and the tirzepatide labels name warfarin as an example of what to watch.
- The window reopens at every dose increase, which makes titration a repeating checkpoint rather than a one-time one.
Answer first: this is not a class effect
The tirzepatide labels, Zepbound and Mounjaro, both carry an explicit instruction for anyone using oral hormonal contraceptives. So does the orforglipron label, Foundayo.
The semaglutide labels do not. Wegovy's drug interactions section states that in clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications. Its clinical pharmacology section names ethinyl estradiol and levonorgestrel among drugs showing no clinically significant difference.
One detail matters more than any of the rest, and all three warning labels say it the same way. Hormonal contraceptives that are not taken by mouth are not expected to be affected.
The mechanism is gastric emptying rather than anything hormonal. A drug that slows the stomach can change how a swallowed pill is absorbed, which is why the warning attaches to the oral form and stops there.
What the tirzepatide labels actually say
The wording is nearly identical on both. Use of the drug may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and the labels state that this delay is largest after the first dose and diminishes over time.
The instruction that follows is specific. Patients using oral hormonal contraceptives are advised to switch to a non-oral method, or to add a barrier method, for four weeks after starting the medication and for four weeks after each dose escalation.
That instruction appears three times on each label rather than once. It is in the highlights, in the drug interactions section, in the section on females and males of reproductive potential, and again in the patient counseling information.
The same drug interactions section adds a wider point. These drugs delay gastric emptying and can therefore affect the absorption of other swallowed medications, and the labels single out drugs with a narrow therapeutic index, naming warfarin as an example.
The measurement underneath the warning
The clinical pharmacology section shows why the label is worded as strongly as it is. A combined oral contraceptive containing ethinyl estradiol and norgestimate was given alongside a single low dose of tirzepatide.
Peak concentrations fell substantially for all three measured components, by more than half in each case. Total exposure over the dosing interval fell by roughly a fifth, and the time to peak concentration was pushed back by several hours.
That pattern is worth reading carefully, because the two numbers say different things. Total exposure moved much less than the peak did, which is the signature of absorption being slowed and spread out rather than blocked.
The same section reports the same shape for acetaminophen. Peak concentration dropped sharply after the first low dose, and by week six at a much higher dose there was no meaningful impact on peak concentration or timing.
That is the evidence behind the phrase about the first dose. The effect is front-loaded, and it fades as the stomach adapts, which is exactly why the counseling window is tied to starting and to each increase.
Orforglipron: same instruction, longer clock, no study
The Foundayo label reaches the same instruction by a different route, and it says so plainly. The effect of the drug on the absorption of oral contraceptives has not been evaluated in a clinical trial.
Its reasoning is stated openly: because delayed gastric emptying may affect the absorption of oral medications, patients using oral hormonal contraceptives are advised to switch to a non-oral method or add a barrier method. The advice is precautionary rather than measured.
The window is longer here. This label specifies 30 days after starting and 30 days after each dose escalation, where the tirzepatide labels specify four weeks.
That label also carries a separate contraception statement of a different kind. Based on animal reproduction studies, it advises women of childbearing potential to use effective contraception during treatment, which is a pregnancy-risk statement rather than an absorption one.
Being a tablet changes the surrounding picture too. This label carries interactions that the injectables do not, including limits tied to strong CYP3A4 inhibitors and inducers and a cap on a concurrently used statin.
What the semaglutide labels say instead
Wegovy's drug interactions section acknowledges the same mechanism and then reports a different result. Semaglutide causes a delay of gastric emptying and could therefore affect absorption, but in clinical pharmacology trials with the once-weekly injection it did not affect the absorption of orally administered medications.
Its clinical pharmacology section names the drugs that were checked. No clinically significant differences in pharmacokinetics were observed for lisinopril, both forms of warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin.
The Ozempic label reports the same finding for the same pair. An oral contraceptive containing ethinylestradiol and levonorgestrel was assessed at steady state, and the label concludes that no clinically relevant interaction was observed and no dose adjustment is required.
The Wegovy label's section on females and males of reproductive potential is present, and it addresses something else. It advises discontinuing at least two months before a planned pregnancy, because of the long half-life of semaglutide.
One exception is worth knowing about, and it belongs to the tablet rather than the injection. In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased by about a third.
Why the moments that matter are starting and stepping up
All three warning labels tie the window to two events rather than to a calendar. One is initiation. The other is each dose escalation.
That follows directly from the measurement. The slowing of the stomach is largest with the first dose at a given level, and it lessens as the body adapts to that level.
So a titration schedule creates a repeating window rather than a single one at the beginning. Someone climbing through several increases passes through the same instruction each time.
This is one of the few places where a dose change has a consequence that is not about side effects or cost. It is worth flagging to whoever prescribes your contraception, who may not be the person prescribing the GLP-1.
The same mechanism reaches beyond contraception
Every one of these labels says some version of the same thing about swallowed medication generally. Delayed gastric emptying can change the absorption of oral drugs taken at the same time.
The tirzepatide labels name the category to watch. Drugs dependent on threshold concentrations for efficacy, and drugs with a narrow therapeutic index, with warfarin given as the example.
The oral GLP-1s carry a different and larger interaction list, because a tablet is also metabolized in ways an injection is not. That is a real difference between the two forms beyond convenience.
None of this is a reason to stop anything. It is a reason for one conversation with a pharmacist who can see your whole medication list at once, which is a thing a comparison site cannot do.
What to ask, and who to ask
Ask which molecule you are actually being prescribed, by its generic name. The instruction differs between tirzepatide, orforglipron and semaglutide, and a program's marketing name is not the answer to that question.
If you take an oral contraceptive, ask the prescriber writing that prescription, not only the one writing the GLP-1. Telehealth programs and contraception prescribers are frequently different offices, and neither automatically sees the other's list.
Ask a pharmacist to run your full list, including anything over the counter. Absorption effects are about what is in the stomach at the same time, which is a question about your whole list rather than about two drugs.
Then read the leaflet in your own carton. It is the label for the exact product you were sent, it is revised more often than any article, and it is where your dose instructions come from.
Sources
- ZEPBOUND (tirzepatide) injection — full prescribing informationThe contraceptive instruction and its four-week window, the note that non-oral methods are unaffected, the measured pharmacokinetics, and the warfarin caution.
- MOUNJARO (tirzepatide) injection — full prescribing informationThat the same contraceptive instruction and oral-medication caution appear on the diabetes label as well as the weight-management one.
- FOUNDAYO (orforglipron) tablet — full prescribing informationThat the effect on oral contraceptive absorption was not studied, the precautionary 30-day instruction, and the CYP3A4 and statin interactions specific to the tablet.
- WEGOVY (semaglutide) injection and tablet — full prescribing informationThat semaglutide did not affect absorption of oral medications in trials, the drug list including ethinyl estradiol and levonorgestrel, and the levothyroxine finding.
- OZEMPIC (semaglutide) injection — full prescribing informationThat an oral contraceptive was assessed at steady state, with no clinically relevant interaction observed and no dose adjustment required.
Frequently asked questions
Do GLP-1s make birth control pills stop working?
Some of them carry a warning about it and some do not, so the answer depends on the molecule. The tirzepatide labels, Zepbound and Mounjaro, state that use may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and advise switching to a non-oral method or adding a barrier method. The orforglipron label, Foundayo, gives the same advice as a precaution, while stating the effect has not been evaluated in a clinical trial. The semaglutide labels report the opposite finding: no clinically significant difference in the pharmacokinetics of ethinyl estradiol or levonorgestrel when given with semaglutide.
Does this affect an IUD, an implant, a patch or a ring?
The labels that carry the warning say it is not expected to. The Zepbound and Mounjaro labels state directly that hormonal contraceptives which are not administered orally should not be affected, and the Foundayo instruction is likewise to switch to a non-oral contraceptive method. That is what the mechanism predicts, because the concern is about absorption of a swallowed pill through a stomach that is emptying more slowly. A method that does not pass through the stomach is not exposed to that effect. Confirm your own method with the prescriber who manages it.
How long does the window last?
It depends on the label, and it is tied to events rather than to a start date. The tirzepatide labels specify four weeks after initiation and four weeks after each dose escalation. The Foundayo label specifies 30 days after initiation and 30 days after each dose escalation. Both attach the window to every increase, not only to the beginning, which means someone titrating upward passes through it repeatedly. The tirzepatide labels explain why: the delay in gastric emptying is largest after the first dose at a given level and diminishes as the body adapts to it.
How big is the effect that was actually measured?
The tirzepatide labels publish it. A combined oral contraceptive with ethinyl estradiol and norgestimate was given alongside a single low dose of tirzepatide. Peak concentrations of all three measured components fell by more than half. Total exposure across the dosing interval fell by roughly a fifth, and the time to peak was delayed by several hours. The gap between those two numbers is the point: exposure moved far less than the peak did, which is what slowed and spread-out absorption looks like rather than blocked absorption. The label reports the same shape for acetaminophen, and shows it fading by week six.
Why does the semaglutide label not carry this warning?
Because the interaction was studied and the result went the other way. The Wegovy label states that in clinical pharmacology trials with the once-weekly injection, semaglutide did not affect the absorption of orally administered medications. Its clinical pharmacology section lists ethinyl estradiol and levonorgestrel among drugs with no clinically significant pharmacokinetic difference. The Ozempic label reports an oral contraceptive containing ethinylestradiol and levonorgestrel assessed at steady state, with no clinically relevant interaction observed and no dose adjustment required. Its section on reproductive potential does carry different advice, about discontinuing well ahead of a planned pregnancy.
Does this apply to compounded semaglutide or compounded tirzepatide?
A compounded product is not an FDA-approved drug and does not come with an FDA-approved prescribing information document, so there is no equivalent label to read. What the approved labels describe is a property of the molecule and of gastric emptying, not of a particular manufacturer's packaging. The practical step is the same either way: tell the prescriber who manages your contraception exactly which molecule you are taking, and ask a pharmacist to review your full list. Anything about what is safe for you specifically is a question for a clinician, not for a comparison site.